Ignite Creation Date:
2025-12-24 @ 11:37 PM
Ignite Modification Date:
2026-03-03 @ 4:15 AM
Study NCT ID:
NCT03636256
Status:
COMPLETED
Last Update Posted:
2023-08-14
First Post:
2018-08-14
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Evaluation of NanoDoce® in Participants With Urothelial Carcinoma
Sponsor:
NanOlogy, LLC
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Bladder Cancer | View |
| None | Urothelial Carcinoma | View |
| None | Urinary Bladder Neoplasm | View |
| None | Urinary Bladder Cancer | View |
| None | Urogenital Neoplasms | View |
| None | Urologic Neoplasms | View |
| None | Urologic Cancer | View |
| None | Malignant Tumor of the Urinary Bladder | View |
| None | Cancer of the Bladder | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | non-muscle invasive bladder cancer | View |
| None | muscle invasive bladder cancer | View |
| None | high-risk bladder cancer | View |
| None | BCG-unresponsive bladder cancer | View |
| None | BCG failure | View |
| None | BCG-refractory bladder cancer | View |
| None | BCG-resistant bladder cancer | View |
| None | NMIBC | View |
| None | MIBC | View |